DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
p38γ is essential for cell cycle progression and liver tumorigenesis
27 páginas, 4 figuras. Contiene material suplementario, método, 6 figuras en: https://doi.org/10.1038/s41586-019-1112-8, The cell cycle is a tightly regulated process that is controlled by the conserved cyclin-dependent kinase (CDK)-cyclin protein complex1. However, control of the G0-to-G1 transition is not completely understood. Here we demonstrate that p38 MAPK gamma (p38γ) acts as a CDK-like kinase and thus cooperates with CDKs, regulating entry into the cell cycle. p38γ shares high sequence homology, inhibition sensitivity and substrate specificity with CDK family members. In mouse hepatocytes, p38γ induces proliferation after partial hepatectomy by promoting the phosphorylation of retinoblastoma tumour suppressor protein at known CDK target residues. Lack of p38γ or treatment with the p38γ inhibitor pirfenidone protects against the chemically induced formation of liver tumours. Furthermore, biopsies of human hepatocellular carcinoma show high expression of p38γ, suggesting that p38γ could be a therapeutic target in the treatment of this disease, s We thank S. Bartlett for English editing, D. Engelberg for
the constitutively active mutants, the Division of Signal Transduction Therapy
for recombinant proteins, and CNIC Advanced Imaging and Vector Units for
technical support. G.S. (RYC-2009-04972), F.J.C. (RYC-2014-15242), and
Y.A.N. (RYC-2015-17438) are investigators of the Ramón y Cajal Program.
E.M. and M.T. were awarded La Caixa fellowships and R.R.-B. was a fellow
of the Fundación Ramón Areces-UAM and FPU. B.G.-T. is a fellow of the FPI
Severo Ochoa CNIC program (SVP-2013-067639). F.J.C. is a Gilead Liver
Research Scholar. This work was funded by grants supported in part by
funds from the European Regional Development Fund: the European Union’s
Seventh Framework Programme (FP7/2007-2013) ERC 260464, EFSD/Lilly
European Diabetes Research Programme Dr Sabio, 2017 Leonardo Grant
for Researchers and Cultural Creators, BBVA Foundation (InvestigadoresBBVA-2017) IN[17]_BBM_BAS_0066, MINECO-FEDER SAF2016-79126-R, and
Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/
BMD-3733 to G.S.; Juan de la Cierva and MINECO SAF2014-61233-JIN to
A.T.-L.; the European Community for MSCA-IF-2014-EF-661160-MetAccembly
grant to F.F.; Spanish MINECO CTQ2014-59212-P, European Community for
CIG project (PCIG14-GA-2013-630978), and European Research Council
(ERC) under the European Union’s Horizon 2020 (ERC-2015-StG-679001-
NetMoDEzyme) to S.O.; the German Research Foundation (SFB/TRR57/P04
and DFG NE 2128/2-1) and MINECO SAF2017-87919R to Y.A.N.; EXOHEP-CM
S2017/BMD-3727 and the COST Action CA17112, MINECO SAF2016-78711,
and the AMMF Cholangiocarcinoma Charity 2018/117 to F.J.C.; MINECO
(SAF2015-69920-R co-funded by ERDF-EU), the Consolider-Ingenio 2010
Programme (SAF2014-57791-REDC), Excellence Network CellSYS (BFU2014-
52125-REDT), and the iLUNG Programme (B2017/BMD-3884) from the
Comunidad de Madrid to M. Malumbres; MINECO SAF2015-67077-R and
SAF2017-89901-R to J.B.; MINECO (BIO2015-67580-P), Carlos III Institute
of Health-Fondo de Investigación Sanitaria (ProteoRed PRB3, IPT17/0019 -
ISCIII-SGEFI/ERDF), Fundación La Marató and ‘La Caixa’ Banking Foundation
(HR17-00247) to J.V.; ISCIII and FEDER PI16/01548 and Junta de Castilla
y León GRS 1362/A/16 and INT/M/17/17 to M. Marcos; Junta de Castilla y
León GRS 1356/A/16 and GRS 1587/A/17 to J.L.-T.; and MCNU (SAF2017-
84494-C2-1-R) to J.R.-C. The CNIC is supported by the Ministerio de Ciencia,
Innovación y Universidades (MCNU) and the Pro CNIC Foundation, and is a
Severo Ochoa Center of Excellence (SEV-2015-0505)., Peer reviewed